跳至主要内容
临床试验/NCT05300542
NCT05300542已完成不适用

Efficacy Study of a Novel Cosmetic Product to Reduce an UVB Induced Erythema

Amazentis SA1 个研究点 分布在 1 个国家目标入组 22 人开始时间: 2022年3月17日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
Amazentis SA
入组人数
22
试验地点
1
主要终点
Visual erythema evaluation by a trained grader on a scale of -2 (marked redness) to 3 (no redness)

研究概览

简要总结

The aim of this study is to determine the erythema-reducing efficacy of a test product in two concentrations on a light sunburn induced by a sun simulator compared to an untreated control and a placebo product.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Basic Science
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Written Informed Consent to participate in the study
  • Willingness to actively participate in the study and to come to the scheduled visits
  • Female and/or male
  • From 18 to 65 years of age
  • Uniform skin color and no erythema or dark pigmentation in the test area
  • ITA° > 28 in the test area

排除标准

  • Female subjects: Pregnancy or lactation
  • Drug addicts, alcoholics
  • AIDS, HIV-positive or infectious hepatitis
  • Conditions which exclude a participation or might influence the test reaction/evaluation
  • Participation or being in the waiting period after participation in cosmetic and/or pharmaceutical studies pertaining to the test area
  • One of the following illnesses with reduced physical capability/fitness: asthma (symptom-free allergic asthma is not an exclusion criterion), hypertension, cardiovascular diseases
  • Cancer not being diagnosed as cured and requiring chemotherapy, irradiation and/or hormonal treatment within the last 2 years
  • Insulin-dependent diabetes mellitus
  • Electronic implant (e.g. pace maker, insulin pump, hearing aid, and the like) that cannot be removed during irradiation
  • Documented allergies to cosmetic products and/or ingredients
  • Active skin disease at the test area
  • Irregularly tanned skin in the test area
  • Medical history of dysplastic nevi, melanoma or other skin carcinoma
  • Medical history of abnormal response to sunlight
  • Regular use of tanning beds (more than 10 times within the last 6 months)
  • Wounds, moles, tattoos, scars, irritated skin, excessive hair growth, etc. at the test area that could influence the investigation
  • Usage of medication with known photo-toxic and/or photo-sensitizing potential (e.g. some antibiotics, blood pressure regulating agents and antidepressants agents; hypericum perforatum) within the last 14 days prior to the start of the study and/or throughout the entire course of the study
  • Any topical medication at the test area within the last 7 days prior to the start of the study and/or throughout the entire course of the study
  • Systemic therapy with immuno-suppressive drugs (e.g. corticosteroids) and/or antihistamines (e.g. antiallergics) within the last 7 days prior to the start of the study and/or throughout the entire course of the study
  • Systemic therapy with anti-phlogistic agents or analgetics (e.g. diclophenac), except for minor pain relief medicine like acetylsalicylic acid or paracetamol within the last 3 days prior to the start of the study and/or throughout the entire course of the study

结局指标

主要结局

Visual erythema evaluation by a trained grader on a scale of -2 (marked redness) to 3 (no redness)

时间窗: 3 days

Erythema (skin redness) assessed by Chromameter

时间窗: 3 days

次要结局

未报告次要终点

研究者

发起方
Amazentis SA
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验